TY - JOUR
T1 - The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland
T2 - results from the LIPIDOGRAM2015 study
AU - LIPIDOGRAM2015 Investigators
AU - Jóźwiak, Jacek J.
AU - Studziński, Krzysztof
AU - Tomasik, Tomasz
AU - Windak, Adam
AU - Mastej, Mirosław
AU - Catapano, Alberico L.
AU - Ray, Kausik K.
AU - Mikhailidis, Dimitri P.
AU - Toth, Peter P.
AU - Howard, George
AU - Lip, Gregory Y.H.
AU - Tomaszewski, Maciej
AU - Charchar, Fadi J.
AU - Sattar, Naveed
AU - Williams, Bryan
AU - MacDonald, Thomas M.
AU - Nowak, Dariusz
AU - Skowron, Łukasz
AU - Kasperczyk, Sławomir
AU - Banach, Maciej
N1 - Funding Information:
JJJ has received research grant/support from Valeant, and has served as a consultant or speaker for Valeant, Amgen, Teva, Servier, Boehringer Ingelheim, Celgene, Bioton, Microlife and ALAB Laboratories. TT has served as a consultant or speaker for Boehringer Ingelheim, Novartis, Shire, Biofarm, Eli Lilly. AW has served as a consultant or speaker for Merck, Boehringer Ingelheim, Sanofi Aventis, Bausch Health. ALC reports grants from Amgen, Sanofi, Regeneron personal fees from Merck, Sanofi, Regeneron, AstraZeneca, Amgen, Novartis, outside the submitted work. DPM has given talks and attended conferences sponsored by Amgen, Novonordisk and Libytec. MTM has no direct competing interests in regards to this paper. His dept holds or has held research grants from Pfizer, Amgen, Ipsen, Shire, Teijin & Menarini. He was or has been the principal investigator on trials paid for by: Pfizer, Novartis, Ipsen, Teijin & Menarini. In the last 5 years have been paid consulting or speakers fees by Novartis, Takeda, Shire, & AstraZeneca. ?S has given talks and attended conferences sponsored by Janssen-Cilag, Pfizer, Krka. SK has served as a speaker for Novartis. MB has received research grant(s)/support from Amgen, Mylan, Sanofi and Valeant, and has served as a consultant for Amgen, Daiichi-Sankyo, Esperion, Freia Pharmaceuticals, Herbapol, Kogen, KRKA, Mylan, Novartis, Novo-Nordisk, Polfarmex, Polpharma, Sanofi-Aventis, Servier, and Zentiva.The present study was an initiative of the Polish Lipid Association (PoLA) and the College of Family Physician in Poland (CFPiP). The present study was funded by an unrestricted educational grant from Valeant. As a supporter of the study, Valeant had no role in study design, data analysis, data interpretation, or writing of the report. The present study was also supported by Silesian Analytical Laboratories (SLA), CHDE, BIO-RAD. The work of ALC has been supported by Ministry of Health - Ricerca Corrente - IRCCS MultiMedica, PRIN 2017H5F943 and ERANET ER-2017-2364981. In addition, we would like to thank all volunteer investigators, all volunteer staff and all participants. The list of the LIPIDOGRAM 2015 investigators is presented in Supplementary material 3. This article is part of a Supplement entitled ?Plasma lipids and cardiovascular risk: Nutritional and therapeutic approaches? published with support from Societ? Italiana di Terapia Clinica e Sperimentale (SITeCS).
Funding Information:
JJJ has received research grant/support from Valeant , and has served as a consultant or speaker for Valeant, Amgen, Teva, Servier, Boehringer Ingelheim, Celgene, Bioton, Microlife and ALAB Laboratories. TT has served as a consultant or speaker for Boehringer Ingelheim, Novartis, Shire, Biofarm, Eli Lilly. AW has served as a consultant or speaker for Merck, Boehringer Ingelheim, Sanofi Aventis, Bausch Health. ALC reports grants from Amgen , Sanofi , Regeneron personal fees from Merck , Sanofi , Regeneron , AstraZeneca , Amgen , Novartis , outside the submitted work. DPM has given talks and attended conferences sponsored by Amgen, Novonordisk and Libytec. MTM has no direct competing interests in regards to this paper. His dept holds or has held research grants from Pfizer , Amgen , Ipsen , Shire , Teijin & Menarini. He was or has been the principal investigator on trials paid for by: Pfizer, Novartis, Ipsen, Teijin & Menarini. In the last 5 years have been paid consulting or speakers fees by Novartis , Takeda , Shire , & AstraZeneca . ŁS has given talks and attended conferences sponsored by Janssen-Cilag , Pfizer , Krka. SK has served as a speaker for Novartis. MB has received research grant(s)/support from Amgen, Mylan, Sanofi and Valeant , and has served as a consultant for Amgen, Daiichi-Sankyo, Esperion, Freia Pharmaceuticals, Herbapol, Kogen, KRKA, Mylan, Novartis, Novo-Nordisk, Polfarmex, Polpharma, Sanofi-Aventis, Servier, and Zentiva.
Funding Information:
The present study was an initiative of the Polish Lipid Association (PoLA) and the College of Family Physician in Poland (CFPiP). The present study was funded by an unrestricted educational grant from Valeant . As a supporter of the study, Valeant had no role in study design, data analysis, data interpretation, or writing of the report. The present study was also supported by Silesian Analytical Laboratories (SLA) , CHDE , BIO-RAD . The work of ALC has been supported by Ministry of Health - Ricerca Corrente - IRCCS MultiMedica , PRIN 2017H5F943 and ERANET ER-2017-2364981. In addition, we would like to thank all volunteer investigators, all volunteer staff and all participants. The list of the LIPIDOGRAM 2015 investigators is presented in Supplementary material 3. This article is part of a Supplement entitled “Plasma lipids and cardiovascular risk: Nutritional and therapeutic approaches” published with support from Società Italiana di Terapia Clinica e Sperimentale (SITeCS).
Publisher Copyright:
© 2021 Elsevier B.V.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Background and aim: To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients. Methods: A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices. Results: Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60% of the recruited patients had hypertension (HTN), >80% had dyslipidaemia and <15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist circumference exceed norm for the European population. Less than half of the patients were current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure and glucose levels but lower low density lipoprotein-cholesterol level. Conclusions: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.
AB - Background and aim: To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients. Methods: A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices. Results: Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60% of the recruited patients had hypertension (HTN), >80% had dyslipidaemia and <15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist circumference exceed norm for the European population. Less than half of the patients were current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure and glucose levels but lower low density lipoprotein-cholesterol level. Conclusions: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.
KW - Cardiovascular disease
KW - Cardiovascular risk factors
KW - Diabetes mellitus
KW - Hypercholesterolaemia
KW - Hypertension
KW - Obesity
KW - Poland
KW - Primary health care
UR - http://www.scopus.com/inward/record.url?scp=85100958638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100958638&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosissup.2021.01.004
DO - 10.1016/j.atherosclerosissup.2021.01.004
M3 - Article
AN - SCOPUS:85100958638
VL - 42
SP - e15-e24
JO - Atherosclerosis Supplements
JF - Atherosclerosis Supplements
SN - 1567-5688
ER -